License agreement for LPLDL®

OptiBiotix Health plc

("OptiBiotix" or the "Company")

LP_LDL® license agreement for new application in hypertension

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that its fully-owned subsidiary ProBiotix Health Ltd. ("ProBiotix"), has signed a license agreement with Nutrilinea Srl. ("Nutrilinea") for the use of LP_LDL® in a food supplement for the reduction of high blood pressure (hypertension). Nutrilinea will cover the cost of all product development, manufacturing and human studies in return for 12 months exclusivity for the European market.  ProBiotix has exclusivity for the UK and all other markets outside Europe.

Nutrilinea, based near Milan in northern Italy, is a manufacturer of food supplement formulations containing probiotics, with over 15 years' experience in the development of products for the food and pharmaceutical industries in Europe and the United States. It is one of OptiBiotix's preferred manufacturers, and currently produces the Company's CholBiome®, CholBiome®_x3 and SlimBiome® Medical products. Nutrilinea has technology that enables the production of multilayer tablets used in CholBiome®_x3 which will also be used for this new product. In an independent human study by the University of Reading, there was a statistically significant reduction in both blood pressure and cholesterol in volunteers taking LP_LDL® compared to a control group (Costabile et al., 2017). The European Cardiovascular Society reported in 2016 that the combination of lowering LDL cholesterol and systolic blood pressure has the potential to "dramatically reduce" a person's lifetime risk of cardiovascular disease.

Hypertension is a global healthcare issue and is one of the strongest risk factors for almost all cardiovascular diseases. The fact that it does not have obvious symptoms have lead doctors to call hypertension a 'silent killer'. Studies conducted in Europe and in the United States suggest that, under new hypertension guidelines, a large percentage of the adult population may be considered hypertensive: some 14 million people in the UK and over 100 million in the US.

https://www.independent.co.uk/news/health/adults-heart-attacks-strokes-early-death-high-blood-pressure-pills-a8247051.html

https://www.heart.org/en/news/2018/05/01/more-than-100-million-americans-have-high-blood-pressure-aha-says  

Dr Luis Gosalbez, Business Development Director of OptiBiotix, commented: "We are delighted to announce this deal with Nutrilinea who are covering the cost of product development, manufacturing and human studies, for a food supplement to reduce blood pressure. This broadens the use of LP_LDL® beyond cholesterol reduction and creates new market opportunities in the field of cardiovascular health. Hypertension is a global health issue which is on the rise where there are very few active ingredients or supplements proven to lower blood pressure in humans. The development of a hypertension product containing LP_LDL® has the potential to address a large global market of unmet clinical need."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.